Latest News

Humana (NYSE:HUM) Upgraded to Buy by ValuEngine

Humana (NYSE:HUM) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Friday, November 8th, ValuEngine reports.

Several other brokerages have also recently weighed in on HUM. UBS Group increased their price target on Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. SunTrust Banks increased their price target on Humana to $335.00 and gave the company a “hold” rating in a research note on Thursday, November 7th. They noted that the move was a valuation call. Deutsche Bank initiated coverage on Humana in a research note on Thursday, September 12th. They issued a “hold” rating and a $300.00 price target for the company. JPMorgan Chase & Co. increased their price target on Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley decreased their price target on Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $327.88.

Shares of HUM traded up $5.43 during mid-day trading on Friday, hitting $343.67. The company’s stock had a trading volume of 59,592 shares, compared to its average volume of 1,043,324. Humana has a one year low of $225.65 and a one year high of $341.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.83 and a current ratio of 1.83. The firm has a market capitalization of $44.82 billion, a PE ratio of 23.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.85. The stock’s 50-day moving average is $293.95 and its two-hundred day moving average is $276.01.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.45. Humana had a return on equity of 22.32% and a net margin of 4.06%. The company had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. During the same period in the prior year, the business earned $4.58 earnings per share. Humana’s revenue for the quarter was up 14.3% compared to the same quarter last year. Analysts expect that Humana will post 17.77 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Cornerstone Advisors Inc. grew its holdings in shares of Humana by 9.9% during the 3rd quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock worth $99,000 after acquiring an additional 35 shares during the period. Lindbrook Capital LLC boosted its position in shares of Humana by 12.0% in the 3rd quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock worth $84,000 after purchasing an additional 35 shares in the last quarter. Regentatlantic Capital LLC boosted its position in shares of Humana by 0.4% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after purchasing an additional 42 shares in the last quarter. Ballentine Partners LLC boosted its position in shares of Humana by 2.5% in the 3rd quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock worth $448,000 after purchasing an additional 42 shares in the last quarter. Finally, Cim Investment Mangement Inc. boosted its position in shares of Humana by 4.3% in the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 46 shares in the last quarter. 94.12% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: What are convertible shares? 

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Leave a Reply

Your email address will not be published. Required fields are marked *